Chardan Capital Comments on MeiraGTx FY2026 Earnings
Analysts at Chardan Capital issued their FY2026 earnings estimates for MeiraGTx in a research report issued on Monday, March 24th. Chardan Capital analyst D. Gataulin anticipates that the company will ...
Chardan Capital Predicts MeiraGTx FY2025 Earnings
Chardan Capital issued their FY2025 earnings estimates for shares of MeiraGTx in a report released on Monday, March 24th. Chardan Capital analyst D. Gataulin anticipates that the company will post ...
MeiraGTx Holdings: Gaining Regulatory Focus
MeiraGTx's innovative gene therapies for ocular diseases & more are backed by strong clinical data and funding. Click here to find out why MGTX stock is a Buy.
Pharmaceutical Technology on MSN14d
MeiraGTx and Hologen launch AI-backed gene therapy venture
The venture aims to advance MeiraGTx’s Parkinson’s gene therapy through Phase III trials with up to $430m in funding from Hologen.
Yahoo Finance16d
MeiraGTx spins Parkinson’s, obesity gene therapies into AI startup
To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Gene therapy specialist MeiraGTx is spinning some of its experimental medicines for the central nervous ...
MeiraGTx rises after deal with Hologen to form joint venture
Shares of MeiraGTx Holdings (NASDAQ:MGTX) traded higher in the premarket on Thursday after the company, with its Q4 2024 results, announced an agreement with AI-focused research firm Hologen Limited ...
MeiraGTx price target raised to $13 from $11 at RBC Capital
RBC Capital raised the firm’s price target on MeiraGTx (MGTX) to $13 from $11 and keeps an Outperform rating on the shares after its Q4 ...
Yahoo Finance4d
MeiraGTx Holdings plc (NASDAQ:MGTX) Is Expected To Breakeven In The Near Future
MeiraGTx Holdings plc (NASDAQ:MGTX) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. MeiraGTx Holdings plc, a clinical stage ...
Forbes23d
This Founder’s Gene Therapy Company Helped Blind Kids See Again
Zandy Forbes’ biotech company MeiraGTx has developed targeted gene therapy methods to treat more than just genetic disorders. Now it’s on the cusp of its first regulatory approval. Each year ...
Morningstar16d
MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates
Today announced strategic collaboration with Hologen AI, including a $200 million upfront payment to MeiraGTx and the formation of a joint venture, Hologen Neuro AI Ltd, with a further $230 ...
RBC Capital Keeps Their Buy Rating on Meiragtx Holdings (MGTX)
In a report released on March 14, Lisa Walter from RBC Capital maintained a Buy rating on Meiragtx Holdings (MGTX – Research Report), with a ...
MeiraGTx Holdings plc (NASDAQ:MGTX) Is Expected To Breakeven In The Near Future
MeiraGTx Holdings plc ( NASDAQ:MGTX ) is possibly approaching a major achievement in its business, so we would like ...